PETROS PHARMACEUTICALS INC (PTPI)

US71678J2096 - Common Stock

0.2944  -0.02 (-5.67%)

After market: 0.26 -0.03 (-11.68%)

Fundamental Rating

2

PTPI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PTPI have multiple concerns. While showing a medium growth rate, PTPI is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PTPI has reported negative net income.
PTPI had a negative operating cash flow in the past year.
In the past 5 years PTPI always reported negative net income.
PTPI had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

PTPI has a worse Return On Assets (-144.12%) than 83.77% of its industry peers.
With a Return On Equity value of -956.75%, PTPI is not doing good in the industry: 84.29% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -144.12%
ROE -956.75%
ROIC N/A
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PTPI has a Gross Margin of 74.74%. This is amongst the best in the industry. PTPI outperforms 81.68% of its industry peers.
In the last couple of years the Gross Margin of PTPI has declined.
The Profit Margin and Operating Margin are not available for PTPI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%

More info and screens

0

2. Health

2.1 Basic Checks

PTPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PTPI has more shares outstanding
Compared to 5 years ago, PTPI has more shares outstanding
PTPI has a better debt/assets ratio than last year.

2.2 Solvency

PTPI has an Altman-Z score of -10.07. This is a bad value and indicates that PTPI is not financially healthy and even has some risk of bankruptcy.
PTPI has a Altman-Z score of -10.07. This is in the lower half of the industry: PTPI underperforms 75.39% of its industry peers.
A Debt/Equity ratio of 1.58 is on the high side and indicates that PTPI has dependencies on debt financing.
PTPI has a Debt to Equity ratio of 1.58. This is in the lower half of the industry: PTPI underperforms 76.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Altman-Z -10.07
ROIC/WACCN/A
WACC7.7%

2.3 Liquidity

PTPI has a Current Ratio of 0.85. This is a bad value and indicates that PTPI is not financially healthy enough and could expect problems in meeting its short term obligations.
PTPI has a worse Current ratio (0.85) than 91.10% of its industry peers.
PTPI has a Quick Ratio of 0.85. This is a bad value and indicates that PTPI is not financially healthy enough and could expect problems in meeting its short term obligations.
PTPI has a worse Quick ratio (0.74) than 87.96% of its industry peers.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.74

More info and screens

5

3. Growth

3.1 Past

The earnings per share for PTPI have decreased strongly by -48.10% in the last year.
Looking at the last year, PTPI shows a very strong growth in Revenue. The Revenue has grown by 46.16%.
PTPI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -16.15% yearly.
EPS 1Y (TTM)-48.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.13%
Revenue 1Y (TTM)46.16%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Sales Q2Q%-5.87%

3.2 Future

PTPI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.87% yearly.
PTPI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.86% yearly.
EPS Next Y58.64%
EPS Next 2Y33.73%
EPS Next 3Y21.34%
EPS Next 5Y14.87%
Revenue Next Year-29.45%
Revenue Next 2Y-15.69%
Revenue Next 3Y-10.88%
Revenue Next 5Y23.86%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTPI. In the last year negative earnings were reported.
Also next year PTPI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PTPI's earnings are expected to grow with 21.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.73%
EPS Next 3Y21.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTPI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PETROS PHARMACEUTICALS INC

NASDAQ:PTPI (12/20/2024, 8:00:01 PM)

After market: 0.26 -0.03 (-11.68%)

0.2944

-0.02 (-5.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners1.67%
Inst Owner Change-19.59%
Ins Owners0.87%
Ins Owner Change0%
Market Cap2.95M
Analysts82.86
Price Target1.02 (246.47%)
Short Float %1.93%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.14%
Min EPS beat(2)-79.18%
Max EPS beat(2)52.89%
EPS beat(4)1
Avg EPS beat(4)-35.9%
Min EPS beat(4)-102.26%
Max EPS beat(4)52.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)7.53%
Min Revenue beat(2)-0.25%
Max Revenue beat(2)15.32%
Revenue beat(4)2
Avg Revenue beat(4)69.07%
Min Revenue beat(4)-6.35%
Max Revenue beat(4)267.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)59.26%
EPS NQ rev (3m)59.26%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.88
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS1.02
BVpS0.31
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -144.12%
ROE -956.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.74%
FCFM N/A
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.74
Altman-Z -10.07
F-Score4
WACC7.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.13%
EPS Next Y58.64%
EPS Next 2Y33.73%
EPS Next 3Y21.34%
EPS Next 5Y14.87%
Revenue 1Y (TTM)46.16%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Sales Q2Q%-5.87%
Revenue Next Year-29.45%
Revenue Next 2Y-15.69%
Revenue Next 3Y-10.88%
Revenue Next 5Y23.86%
EBIT growth 1Y-74.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.16%
OCF growth 3YN/A
OCF growth 5YN/A